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Epstein-Barr virus (EBV) DNA load in the blood increases in post-transplant 27 
lymphoproliferative disorders and chronic active EBV infection. In this report, we analyzed 28 
the EBV DNA load in the peripheral blood mononuclear cells (PBMCs) and plasma of 29 
patients with hydroa vacciniforme (HV) and/or hypersensitivity to mosquito bites (HMB) to 30 
understand the clinical significance of EBV DNA load. All 30 patients showed high DNA 31 
loads in the PBMCs over the cut-off level. Of 16 plasma samples, extremely high in two 32 
samples obtained from patients with hemophagocytic lymphohistiocytosis (HLH). The 33 
amount of cell-free DNA in plasma were correlated to the serum levels of lactate 34 
dehydrogenase, and inversely correlated to platelet counts. These results indicate that the 35 
EBV DNA load in PBMCs can provide one of the diagnostic indicators for HV and HMB and 36 
marked elevation of cell-free EBV DNA in plasma might be related to cytolysis such as that 37 
observed in HLH. 38 
 39 
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Epstein-Barr virus (EBV)-associated T/NK lymphoproliferative disorders (LPDs) include 44 
chronic active EBV infection (CAEBV), hydroa vaccniforme (HV) and hypersensitivity to 45 
mosquito bite (HMB).1,2 HV was first reported as a benign photosensitivity disorder of 46 
childhood, characterized by vesiculopapules on sun-exposed areas. In contrast to this classic 47 
type of HV (classic HV: cHV), patients with a severe form of HV associated with edematous 48 
face, fever, liver damage, and serious hemophagocytic lymphohistiocytosis (HLH) have been 49 
reported mainly from the Eastern Asia and Central America under the name of systemic HV 50 
(sHV).3,4 The patients of sHV was listed in the WHO classification as HV-like LPD. On the 51 
other hand, patients with HMB, or SMBA in the WHO classification 2, are characterized by 52 
skin ulcers and swelling at the sites of mosquito and other insect bites or injection sites for 53 
vaccinations, and frequently show fever and lymphadenopathy. 5-7 Patients with HMB are 54 
also encountered in the endemic areas similar to those of sHV/HV-like LPD and CAEBV. 55 
Unlike patients with cHV, patients with sHV, HMB or CAEBV show a progressive disease 56 
with often fatal outcomes. 4.8 Jeffrey I. Cohen et all reported that in the WHO classification, 57 
CAEBV is divided into two major forms: systemic CAEBV and cutaneous CAEBV; overlap 58 
occurs with some patients with cutaneous CAEBV exhibiting clinical and pathological 59 
evidence of systemic EBV infection. The two main forms of cutaneous CAEBV include HV-60 
like LPD and severe mosquito bite allergy (SMBA). 1  61 
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Patients with cHV and HMB usually have a dominant clone of EBV-infected T cells 62 
and NK cells, respectively.9 Patients with sHV without HMB are classified into two groups: 63 
T-cell-dominant or T-cell-dominant types. Since the patients may have different subsets 64 
of EBV-infected T/NK cells in the blood, the clinical manifestations of HV, HMB and 65 
CAEBV often overlap with each other in the clinical course. 3  66 
The increase of EBV DNA load in the peripheral blood is closely related to the 67 
occurrence of EBV-associated LPDs in recipients with organ or hematopoietic stem cell 68 
transplant. 10.11 Such EBV-associated LPDs are mainly caused by EBV-infected B cells. 69 
However, little is known about the clinical significance of EBV DNA load in patients with 70 
EBV-associated T/NK LPDs such as HV and HMB. Previously, Kimura et al. and our group 71 
reported that the EBV DNA load in the peripheral blood showed no relation to the survival 72 
rate of the patients with CAEBV, HV or HMB. 4.8   73 
As reported previously, EBV is latently infected in the patient’s peripheral blood 74 
mononuclear cells (PBMCs) in an episomal fashion in most cases, 12 and cell-free EBV DNA 75 
fragments are mainly detected in the plasma. 13-15 Therefore, the EBV DNA loads measured 76 
separately in the PBMCs and plasma may have different meanings in different disease 77 
conditions. For instance, the EBV DNA load in plasma is generally high in patients with 78 
EBV-related hemophagocytic lymphohistiocytosis (HLH) or infectious mononucleosis (IM). 79 
16  80 
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In the present study, we measured the EBV DNA load separately in PBMCs and plasma 81 
samples obtained from patients with HV and HMB, and compared the results with clinical 82 
manifestations such as the disease subtype and disease severity, and laboratory data including 83 


















1. Material and Method: 100 
1.1. Patients 101 
A total of 30 patients including 12 patients with cHV, 9 with sHV, 5 with HMB only, 102 
and 4 with HMB associated with HV-like eruptions were enrolled (Table 1).  The control 103 
peripheral blood samples were obtained from 4 patients with IM and 24 healthy individuals. 104 
This study was approved by our ethical committee (the institutional review board of 105 
Okayama University Hospital) in accordance with the 1975 Declaration of Helsinki. 106 
1.2. Real-time PCR  107 
DNA was extracted from PBMCs of these patients at our hospital first visit or during their 108 
clinical courses using a QIAamp™ Blood Kit (Qiagen, Netherlands), and polymerase chain 109 
reaction (PCR) amplification was performed using QuantiTect™ Probe PCR (Qiagen, 110 
Netherlands) by a Roche light cycler (Roche, Switzerland). The PCR primers for this assay 111 
were selected in the BamHI M region. We detected the EBV DNA loads in PBMCs and 112 
plasma using this method. 3.4,9,13 113 
1.3.  Detection of cell-free EBV DNA with DNase treatment 114 
Cell-free EBV DNA consists of encapsidated virions or naked genomes derived from dying 115 
cells. Naked viral DNA was degraded by DNase I, but the viral capsid protects encapsidated 116 
virions from DNase I-digestion. After incubation of plasma samples (200μL) with or without 117 
25μL DNase I (Promega, Madison) for 1hr at 37℃, DNA was extracted with QIAamp DNA 118 
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mini Kit (Qiagen, Netherlands). The EBV DNA load in plasma was measured as described 119 
above. EBV virion levels in plasma were calculated by the ratio of DNase I-treated EBV 120 
DNA load to DNase I-untreated EBV DNA load. Our previous study confirmed that the cell-121 
free EBV DNA in the plasma of 7/9 patients with HV and/or HMB (77.8 %) exclusively 122 
consisted of the naked form of EBV genomes sensitive to DNase treatment. 13 123 
1.4. Reverse transcriptase (RT)-PCR 124 
RNA was extracted from the samples with TRIZOLTM reagent (Gibco BRL, Gaithersburg, 125 
MD), and the cDNA was generated with random hexamer (Takara). The EBV reactivation 126 
marker, BZLF1 was amplified by RT‐PCR, using BZLF1‐specific outer primers as previously 127 
described. 17.18 The integrity of the RNA was checked by the parallel amplification of beta‐2‐128 
microglobulin (β2‐MG). 129 
1.5. Statistical analysis 130 
We analyzed the relation of the characteristic skin symptoms, such as vesiculo-papules, 131 
erythema and scale crusts, and the DNA load during each patient’s clinical course. The 132 
DNA load at the first visit was evaluated in relation to the routine laboratory test results and 133 
outcomes of patients using SPSS Windows version 20.0 software. Fisher’s test and the 134 
Mann-Whitney t-test were used to evaluate differences among groups (P <0.05). 135 
Relationships between the DNA load in PBMC and plasma, or the DNA load and routine 136 
laboratory tests were evaluated using Pearson’s test.  137 
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2. Results 138 
2.1.  Cellular and cell-free EBV DNA load in patients with IM, HV and HMB 139 
The majority of healthy adults are known to possess a small number of EBV-infected B cells 140 
in the peripheral blood. Thus, we measured EBV DNA loads in PBMCs (n=30) and plasma 141 
samples (n=21) obtained from healthy individuals. In these individuals, the EBV DNA load 142 
ranged from 0.5 to 108 copies㎍ DNA in the PBMCs, and from 50 to 100 copies/mL in the 143 
plasma samples. The EBV DNA load in plasma (4/4 cases) were exclusively composed of 144 
cell-free EBV DNA fragments, sensitive to DNase-treatment. Based on these findings, we 145 
determined the cut-off values as follows: 120 copies/㎍ DNA (the mean+3SD) for PBMCs, 146 
and 130 copies/mL (the mean+3SD) for plasma samples. 147 
   Then, we measured EBV DNA loads in 30 samples of PBMCs and 16 plasma samples 148 
from patients with EBV-associated T/NK LPDs including HV and HMB. The EBV DNA 149 
loads in these PBMCs ranged from 446 to 140,000 copies/㎍ DNA (the mean: 28,486 copies/150 
㎍ DNA), all of which were higher than the cut-off value. The EBV DNA loads in the 151 
plasma samples ranged from 0 (detection limit) to 50,000 copies/mL (the mean: 8,446 152 
copies/mL), and 3 of the 16 samples were below the cut-off value (Figure 1). Of the 16 153 
plasma samples, two samples obtained from patients with active HLH showed extremely high 154 
levels of cell-free DNA (50,000 and 28,600 copies/mL, respectively) (Figure 1). There was 155 
no relation between PBMC and plasma levels of the patients with HV and HMB (r=0.21). 156 
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The EBV DNA load in PBMC or plasma showed no relation to the survival rate of the 157 
patients with HV and HMB (Figure 2.). The 5 of 6 patients with sHV died. The main cause of 158 
death was one patient from bowel bleeding, one from HLH, one from multiorgan failure, 159 
which showed invasion of EBV positive T cells in the esophagus, gastrointestinal tract and 160 
myocardium, and two from unknown. The 2 of 9 patients with HMB only and HMB+HV 161 
died. The main cause of death was related to HLH in one HMB patient and was unknown in 162 
one HMB+HV (Table 1). 163 
In patients with IM characterized by primary infection of EBV to B cells (n=4), all patients 164 
except one had higher levels of EBV DNA loads in the PBMCs than the cut-off value, 165 
ranging from 13.3 to 2,680 copies/㎍ DNA, but the mean EBV DNA load in the PBMCs of 166 
the IM group (mean: 1,783 copies/㎍ DNA) was much lower than that of the HV and/or 167 
HMB group (mean: 28,486 copies/㎍ DNA) (Figure 1).   168 
Correlation of EBV DNA load to the disease subtype, severity, and other laboratory 169 
data  170 
Of the 30 PBMC samples examined, the PBMC EBV DNA loads ranged from 770 to 73,000 171 
copies/㎍ DNA (mean: 15,948) in patients with cHV, 446 to 101,000 copies/㎍ DNA 172 
(mean: 37,736) in patients with sHV, and 1,900 to 140,000 copies/㎍ DNA (mean; 41,653) 173 
in patients with HMB with or without HV. There was no correlation between each clinical 174 
subtype, even though the dominant EBV-infected lymphocyte subsets and their numbers 175 
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varied. Our series of patients with cHV (patient 2 in Table 1) , who were in a stable disease 176 
condition, had high EBV DNA loads (73,000 copies/㎍), comparable to those of other 177 
subtypes, sHV and HMB, which had more serious disease or fatal outcome. 178 
When cellular EBV DNA loads were monitored in the same patient with HV-like lesions, 179 
there was no clear correlation to the severity of cutaneous manifestations. The expression of 180 
the EBV reactivation marker, BZLF1 mRNA, is not related to the DNA load in PBMC or 181 
plasma (Table 1). The cellular EBV DNA loads in the PBMCs (n=30) showed no correlation 182 
to the following laboratory test results: white blood cell (WBC) counts, lymphocyte numbers, 183 
hemoglobin (Hb), platelet (PLT) counts, lactate dehydrogenase (LD), aspartate 184 
aminotransferase (AST), alanine transaminase (ALT) (Figure 3), or lymphocyte numbers, 185 
atypical lymphocyte numbers, and ferritin (data not shown). However, there was a relation 186 
between the cellular EBV DNA loads in the PBMCs and soluble interleukin-2 receptor (sIL-187 
2R) (r=0.74) (Figure 3). Therefore, the results of EBV DNA loads in the PBMCs did not 188 
differentiate the benign subtype from the serious subtypes or represent the severity of the 189 
clinical course. 190 
In contrast, the amounts of cell-free EBV DNA in the plasma samples (n=16) were 191 
correlated to elevated levels of serum LD and ALT, respectively (r=0.90 and 0.66), and 192 
reversely correlated to the PLT counts (r=-0.68) (Figure 3).  The two patients with 193 
extremely high levels of cell-free EBV DNA in the plasma (patients 15 and 26 in Table 1) 194 
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showed high levels of LD (764 and 575 IU/L), and AST (48 and 17 IU/L), and low PLT 195 
counts (3.1 and 8.4 x 104/L).  196 
2.2.  Patients with extremely high levels of cell-free EBV DNA in the plasma 197 
Table 1: patient 15 (the same patient as in Ref. 19) 198 
A 7-year-old girl of sHV presented with an abrupt onset of fever of 38 ℃, discharge blood and 199 
aphtha. The blood counts revealed white blood cells at 20500/L, hemoglobin (6.9 g/dl), Plt 200 
(28.5 x 104/L), LD (204 IU/L), AST (22 IU/L), and ALT (12 IU/L). Her colon lesions showed 201 
many CD8-positive cells and EBER-positive cells. After 4 months, she presented with vesicle-202 
papules and scarring on her leg. Her skin lesions were waxed and waned and were treated 203 
with steroid pulse, cyclophosphamide or cyclosporine.  204 
After about 21 months, she had a high-grade fever, and her blood counts revealed white 205 
blood cells at 900/L, thrombocytopenia at 3.1 x 104/L, and an increased percentage 206 
(86.3%) of CD8 cells. The elevated serum levels of LD (764 IU/L), AST (48 IU/L), ALT 207 
(75 IU/L), sIL-2 receptor (4,500 U/mL) and ferritin (371.3 ng/mL), and the increase of 208 
nucleated cells (130000/μl) and blood phagocytosis in bone marrow test, together with 209 
thrombocytopenia, suggested the occurrence of HLH.  210 
The EBV DNA loads in PBMCs and plasma revealed 80,000 copies/㎍ DNA and 50,000 211 
copies/mL, respectively. She was diagnosed as having HLH associated with CAEBV, and 212 
was initially treated with methylprednisolone pulse (20mg/kg/day×3 day) and intravenous 213 
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immunoglobulin, followed by cord blood transplantation with a successful outcome (Table 214 
2). 215 
Table 1: patient 26 (the same patient as in Ref. 20) 216 
A 15-year-old Japanese boy with CAEBV had a 12-year history of HMB. His complete blood 217 
counts revealed a normal range of white and red blood cells, thrombocytopenia (8.4 x 218 
104/L), and an increased percentage (40%) of NK cells with a CD2+, CD3-, CD4-, CD8-, 219 
CD16-, CD56+ phenotype. The elevated serum levels of LD (575 IU/L), AST (17 IU/L), 220 
ALT (79 IU/L), sIL-2R (4,760 U/mL) and ferritin (268 ng/mL), together with 221 
thrombocytopenia, suggested the occurrence of HLH. The patient was treated with a daily 222 
dose of prednisolone, 10 mg, and the dosage was increased to 40 mg/d when systemic 223 
symptoms, such as a high grade fever and splenomegaly, appeared. The cellular EBV DNA 224 
load in the PBMCs was moderately elevated (1,900 copies/㎍ DNA), while the cell-free 225 
EBV DNA in plasma had increased up to 28,600 copies/mL. A bone marrow transplant was 226 
prepared from an HLA-matched donor because of disease progression, but unfortunately the 227 








The present study showed that all 30 patients with HV and HMB had high EBV DNA loads 234 
in the PBMCs, well over the cut-off value (120 copies/㎍ DNA), while only 3 of 16 patients 235 
contained cell-free EBV DNA in the plasma at levels over the cut-off value (130 copies/ml). 236 
Our data indicate that the measurement of EBV DNA load in the PBMCs provides a reliable 237 
diagnostic indicator for HV and HMB, as compared with the detection of cell-free EBV DNA 238 
in plasma. This is the same result of the patients with CAEBV by Ito and Kimura et al. 21.22 239 
But this is the opposite result of the previous observations in a largely immunocompromised 240 
and hospitalized cohort by Kanakry et al: 23 In their study, the cell-free EBV DNA in plasma 241 
performs better than the cellular EBV DNA load in PBMCs. The discrepancy must derive 242 
from differences in the host immunological conditions and the cell lineage with EBV 243 
infection: mainly B-cells in immunocompromised hosts, and T/NK cells in HV and HMB.  244 
There was no correlation between the EBV DNA loads and the clinical features of HV 245 
and HMB, including the disease subtype, disease severity, prognosis, major EBV-infected 246 
lymphocyte subset, and cell numbers. But the monitoring of the cellular EBV DNA load in 247 
PBMCs does not necessarily provide useful information for disease progression and the 248 
occurrence of serious complications. The observation periods of some patients are relatively 249 
short, so we need more follow up times for prognosis. 250 
Among 16 plasma samples from HV and HMB, two plasma samples revealed extremely 251 
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high levels of cell-free EBV DNA; these were obtained from patients complicated with HLH. 252 
Our results corresponded well with previous observations that patients with EBV-associated 253 
HLH or IM generally showed high EBV DNA loads in PBMCs and plasma. 24 Regarding the 254 
pathogenesis of IM and HLH, EBV-infected cells are induced to cell death by host immune 255 
responses or apoptosis, and cellular EBV DNA is released from the cells. 13-15 Our previous 256 
data showed that the cell-free EBV DNA in plasma exclusively consisted of naked EBV 257 
DNA derived from cytolysis in patients with HV and HMB.13  Furthermore, Kawada et al 258 
showed that the plasma DNA load of the patients with CAEBV were significantly high 259 
during the active diseases. 25 Thus, we compared the amounts of cell-free EBV DNA with 260 
blood test results related to cytolysis. The results showed that the amount of cell-free DNA 261 
was correlated to the serum levels of LD, and inversely correlated to the PLT counts in our 262 
series (Figure 3.). These results were strongly affected by the two patients with HLH.  263 
We investigated the plasma of the patient 15, treated with or without DNase-treatment by 264 
using real-time PCR method. DNase-treatment resistant EBV DNA ratio (the DNA treated 265 
with DNase-treatment/ the DNA treated without DNase-treatment) in the plasma were 266 
13.85% before HLH, and 0% during HLH. Therefore, increased levels of cell-free EBV DNA 267 
in the plasma might be related to cytolysis of EBV-infected cells and an alert for serious 268 





The measurement of cellular EBV DNA load in PBMCs provides a diagnostic indicator 272 
for HV and HMB but does not reflect the clinical subtypes or outcomes. The amount of cell-273 
free DNA in plasma is less useful as a diagnostic indicator, but its marked elevation might be 274 
related to serious complications such as HLH.  275 
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Figure legends. 381 
23 
 
Figrue 1. The EBV DNA load in PBMCs, but not in plasma, has a diagnostic value for 382 
HV and HMB.  383 
 All 30 HV/HMB patients showed significantly higher levels of DNA in the PBMCs than 384 
those of healthy individuals. Patients with sHV (□) and HMB (○) showed HLH. 385 
Figure 2. The relation of outcome and EBV DNA load or the EBV DNA load in PBMC 386 
and plasma.  387 
There were no correlations between the EBV DNA load and the patient’s outcome or the 388 
EBV DNA load in PBMC and plasma (r=0.21). 389 
Figure 3. The relations of EBV DNA loads in PBMCs and plasma and routine 390 
laboratory tests results. 391 
The EBV DNA load in plasma showed a close correlation with PLT, LD and ALT, 392 
respectively (r= -0.68, 0.90 and 0.66). 393 
Figure1-3 Abbreviation： HV: hydroa vaccniforme, HMB: hypersensitivity to mosquito bite, 394 
IM: infectious mononucleosis PBMC: peripheral blood mononuclear cell, HLH: 395 
hemophagocytic lymphohistiocytosis,  WBC: white blood cell, Hgb: hemoglobin, Plt: 396 
platelet, LDH: lactate dehydrogenase, AST: aspartate aminotransferase, ALT: alanine 397 
transaminase, sIL2R: soluble interlukin-2 receptor.  398 
 399 
Table legend.    400 
Table 1. The list of 30 patients with HV and/or HMB. 401 
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Table 2. These patients with sHV or HMB of HLH.  402 





Abbreviation：f: female, m: male, cHV: classical hydroa vaccniforme, sHV: systemic hydroa vaccniforme, HMB: hypersensitivity to mosquito 
bite, CAEBV: chronic active Epstein-Barr virus infection, WBC: white blood cell, Ly: lymphocyte, Aty: atypical lymphocyte,  Plt: platelet, LDH: 
















subset gd (/μl) ab (/μl) NK (/μl)
1/f/5 cHV 10 5050 1398.9/0 12.5 20.6 193 17/9 ND ND A ND/1100 - ND ND ND
2/m/3 cHV 4 14490 7389.9/144.9 12.8 27.1 244 30/16 1010 18 A ND/73000 - ND ND ND
3/f/4 cHV 7 8200 3690/0 12.8 29.1 213 25/11 ND ND A ND/11000 - ND ND ND
4/m/1 cHV 2 7440 3742/0 11.8 36.4 257 34/12 ND ND A 2120/12000 - γδ 409.2 1647.3 242
5/m/5 cHV 4 6980 2959/0 12.7 27.6 239 28/11 ND ND A ND/1500 - γδ 548.1 1428.5 228
6/m/5 cHV 5 7000 3350/0 13.6 36.2 393 22/17 ND ND A ND/770 - ND ND ND
7/m/4 cHV 10 5100 892.8/0 12 24.3 425 27/18 323 ND A 1060/3610 - γδ 154 1354 234
8/f/5 cHV 9 4900 2205/0 ND 30.6 255 28/15 ND ND A ND/12000 - ND ND ND
9/f/6 cHV 1 5420 ND/ND 12.5 17.1 218 47/49 ND ND A ND/1000 - γδ ND ND ND
10/m/5 cHV 3 6410 3200/0 12 26.4 292 27/13 ND ND A 1275/29300 - γδ 240 2030 356
11/f/17 cHV 3 4720 2200/0 14.9 19.5 161 20/13 ND ND A 0/ 36100 - γδ 299 1335 173
12/f/8 cHV 4 6150 3198/0 13 25.7 229 53/51 ND ND A 1070/10000 - γδ→NK 187.9 922.4 721.9
13/m/6 sHV 4 5700 3169.2/0 14.3 24.4 238 21/14 ND ND A ND/46000 - ND ND ND
14/f/17 sHV 7 3900 819/0 11.4 18.7 200 24/26 ND 115.1 A ND/3500 - ND ND ND
15※/f/5 sHV 6 1100 583/22 8.5 3.1 764 48/75 4500 371.3 A 50000/80000 - ND ND ND
16/f/17 sHV 7 3940 1059.8/0 10.6 21.2 308 36/28 ND ND D 811/446 + ND ND ND
17/f/25 sHV 9 12800 2560/0 12 29.1 189 30/35 ND 65.6 D 1460/101000 + αβ 0 12416 3200
18/f/10 sHV 8 5800 2204/0 12.9 17.5 124 20/17 14.6 ND D 800/35000 ND ND ND ND
19/m/13 sHV 4 5170 ND/ND 13.9 22.4 200 17/9 ND ND A 0/3160 - αβ 46 1506 66
20/f/68 sHV 14.1 NC ND/ND ND ND ND ND/ND ND ND D 0/6520 + αβ ND ND ND
21/m/74 sHV 4.5 6200 ND/ND 11.3 9.2 300 216/116 ND ND D 13000/64000 + αβ 7.75 1444.6 511.5
22/m/6 HMB 5 3700 1258/37 12.4 5.1 318 30/22 108 ND A ND/5700 + NK ND 1157 1182
23/f/8 HMB 3 8800 7110/0 12.1 11.6 400 221/400 55 ND A ND/28000 - NK ND ND ND
24/m/6 HMB 3 4870 1821/0 12.2 18.2 251 26/10 ND ND A 368/5580 - NK 70 597 931
25/m/5 HMB 3 5200 ND/ND 11.1 16.9 454 52/62 ND ND A ND/140000 ND NK ND ND ND
26※/m/3 HMB 4 8380 ND/ND 15.2 8.4 575 17/79 4760 268 D 28600/1900 + NK ND ND 1681
27/m/20 HMB+HV 14 4900 1900/0 15.3 19.6 166 21/19 ND ND D 1070/31700 + NK ND ND 1681
28/f/8 HMB+HV 2 7780 4745.8/0 12 35.7 266 38/34 34.8 531 A 8160/21000 - NK ND 465 1788
29/f/4 HMB+HV 19 3310 1095/0 12.6 27.5 243 23/10 ND ND A ND/78700 ND NK ND 409 726
30/f/2 HMB+HV 1 5600 ND/ND 12.7 23.8 386 130/151 ND ND A ND/11000 ND NK ND ND ND
26 
 
lactate dehydrogenase, AST: aspartate aminotransferase, ALT: alanine transaminase, sIL2R: soluble interlukin-2 receptor, y: years, Dead: D, 
Alive: A, ND: not done, undetectable=0 , HLH: hemophagocytic lymphohistiocytosis. Patient No 20: ref 26. Patient No 21: ref 27. 



























Abbreviation：HMB: hypersensitivity to mosquito bite, sHV: systemic hydroa vaccniforme, HLH: hemophagocytic lymphohistiocytosis, AST: 
aspartate aminotransferase, ALT: alanine transaminase, LDH: lactate dehydrogenase, Plt: platelet, ND: not done, day0 : the occurrence of HLH. 
 
